Exhibit 10.1
EDGEWISE THERAPEUTICS, INC.
OUTSIDE DIRECTOR COMPENSATION POLICY
(as amended and restated March 2, 2023)
Edgewise Therapeutics, Inc. (the “Company”) believes that the granting of equity and cash compensation to members of the Company’s Board of Directors (the “Board,” and members of the Board, “Directors”) represents an effective tool to attract, retain and reward Directors who are not employees of the Company (“Outside Directors”). This Outside Director Compensation Policy (the “Policy”) is intended to formalize the Company’s policy regarding cash compensation and grants of equity awards to its Outside Directors. Unless otherwise defined herein, capitalized terms used in this Policy will have the meaning given such term in the Company’s 2021 Equity Incentive Plan, as amended from time to time, or if such plan no longer is in use at the time of the grant of an equity award, the meaning given such term or similar term in the equity plan then in place under which the equity award is granted (the “Plan”). Each Outside Director will be solely responsible for any tax obligations incurred by such Outside Director as a result of the equity awards and cash and other compensation such Outside Director receives under this Policy.
Non-Executive Chair of the Board: | $30,000 |
Audit Committee Chair: | $15,000 |
Audit Committee Member: | $7,500 |
Compensation Committee Chair: | $10,000 |
Compensation Committee Member: | $5,000 |
Nominating and Corporate Governance Committee Chair: | $8,000 |
Nominating and Corporate Governance Committee Member: | $4,000 |
For clarity, each Outside Director who serves as the chair of a committee will receive only the additional annual fee as the chair of the committee and not the additional annual fee as a member of such committee while serving as such chair, provided, that the Outside Director who serves as the Chair of the Board will receive the annual fee for services provided in such role as well as the annual fee as an Outside Director.
2
3
4
* * *
5